PDUFA dates February 2022: FDA calendar and catalysts.
0 PDUFA dates fell in February 2022. The FDA calendar also recorded 11 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
PDUFA dates in February 2022
No PDUFA dates are disclosed for this period as of November 16, 2026.
Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months
February 2022: other FDA decisions and filings
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Feb 2022Month disclosed | PYRUKYND® | AGIO | FDA approval | — | Approved | SEC Form 10-K |
| February 3, 2022 | Xigduo Xr (dapagliflozin; metformin hydrochloride) | AZN | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 4, 2022 | KEYTRUDA® (pembrolizumab) | MRK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 15, 2022 | Iclusig (ponatinib hydrochloride) | TAK | Label expansion | — | Approved | openFDA Drugs@FDA |
| February 22, 2022 | — | MENS | NDA/BLA accepted | — | Completed | sec_424b |
| February 25, 2022 | Acuvue Theravision With Ketotifen (ketotifen fumarate) | JNJ | FDA approval | — | Approved | openFDA Drugs@FDA |
| February 28, 2022 | Yeztugo® (lenacapavir) | GILD | Complete Response Letter | — | CRL issued | FDA Complete Response Letters |
| February 28, 2022 | CARVYKTI (ciltacabtagene autoleucel) | LEGN | FDA approval | with relapsed or refractory multiple myeloma | Approved | SEC 8-K Exhibit 99.1 |
| February 28, 2022 | ALUNBRIG (brigatinib) | TAK | Label expansion | — | Approved | openFDA Drugs@FDA |
February 2022: dated readouts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Feb 2022Month disclosed | sepofarsen | PRQR | Topline readout | — | Missed primary endpoint | SEC Form 10-K |
| Feb 2022Month disclosed | — | VALN | Topline readout | — | Positive | SEC Form 10-K |
Questions
What PDUFA dates are in February 2022?
0 PDUFA dates fell in February 2022. The FDA calendar also recorded 11 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.
Can these dates change?
Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.